Teladoc Health (NYSE:TDOC) PT Lowered to $18.00

Teladoc Health (NYSE:TDOC) had its price target cut by Royal Bank of Canada from $25.00 to $18.00 in a report released on Friday, Benzinga reports. They currently have an outperform rating on the health services provider’s stock.

A number of other equities analysts have also recently weighed in on the stock. DA Davidson decreased their price objective on shares of Teladoc Health from $22.00 to $18.00 and set a neutral rating for the company in a research report on Wednesday, February 21st. Piper Sandler lowered their price objective on Teladoc Health from $30.00 to $25.00 and set an overweight rating for the company in a research note on Wednesday, February 21st. Truist Financial cut their target price on Teladoc Health from $23.00 to $17.00 and set a hold rating on the stock in a research report on Wednesday, March 6th. SVB Leerink began coverage on Teladoc Health in a research note on Monday, February 26th. They set a market perform rating and a $17.00 target price for the company. Finally, TD Cowen dropped their price target on shares of Teladoc Health from $16.00 to $15.00 and set a hold rating for the company in a research note on Friday. Twelve research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Teladoc Health presently has an average rating of Hold and a consensus price target of $18.73.

Teladoc Health Price Performance

TDOC stock opened at $13.40 on Friday. The stock has a 50-day simple moving average of $14.69 and a 200-day simple moving average of $17.67. The firm has a market cap of $2.27 billion, a P/E ratio of -9.50 and a beta of 0.94. The company has a debt-to-equity ratio of 0.66, a quick ratio of 3.47 and a current ratio of 3.54. Teladoc Health has a 1 year low of $12.65 and a 1 year high of $30.41.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Thursday, April 25th. The health services provider reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). The firm had revenue of $646.13 million for the quarter, compared to analysts’ expectations of $637.31 million. Teladoc Health had a negative net margin of 8.90% and a negative return on equity of 10.11%. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.37) EPS. On average, equities analysts predict that Teladoc Health will post -1.06 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Jason N. Gorevic sold 53,755 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $780,522.60. Following the completion of the transaction, the chief executive officer now directly owns 653,073 shares of the company’s stock, valued at $9,482,619.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CAO Richard J. Napolitano sold 3,765 shares of Teladoc Health stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $54,667.80. Following the sale, the chief accounting officer now directly owns 18,077 shares in the company, valued at approximately $262,478.04. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Jason N. Gorevic sold 53,755 shares of the business’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.52, for a total transaction of $780,522.60. Following the transaction, the chief executive officer now directly owns 653,073 shares of the company’s stock, valued at $9,482,619.96. The disclosure for this sale can be found here. Insiders have sold a total of 135,441 shares of company stock worth $2,038,251 over the last quarter. 1.63% of the stock is owned by company insiders.

Institutional Investors Weigh In On Teladoc Health

Hedge funds have recently made changes to their positions in the business. Lecap Asset Management Ltd. bought a new position in Teladoc Health in the 4th quarter worth approximately $1,530,000. Sowell Financial Services LLC boosted its position in Teladoc Health by 40.8% during the 4th quarter. Sowell Financial Services LLC now owns 18,907 shares of the health services provider’s stock worth $407,000 after acquiring an additional 5,475 shares during the period. Deutsche Bank AG boosted its position in Teladoc Health by 12.4% during the 3rd quarter. Deutsche Bank AG now owns 301,147 shares of the health services provider’s stock worth $5,598,000 after acquiring an additional 33,287 shares during the period. Sherbrooke Park Advisers LLC bought a new position in shares of Teladoc Health in the third quarter worth $680,000. Finally, QRG Capital Management Inc. acquired a new position in shares of Teladoc Health during the third quarter valued at $392,000. Institutional investors own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.